{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T12:07:54Z","timestamp":1759838874474},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,7,1]],"date-time":"2018-07-01T00:00:00Z","timestamp":1530403200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2018,7]]},"DOI":"10.1016\/j.mcna.2018.02.006","type":"journal-article","created":{"date-parts":[[2018,6,19]],"date-time":"2018-06-19T11:32:44Z","timestamp":1529407964000},"page":"683-696","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Nontraditional Alcohol and Opioid Agonist Treatment Interventions"],"prefix":"10.1016","volume":"102","author":[{"given":"Christopher","family":"Fairgrieve","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey H.","family":"Samet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seonaid","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.mcna.2018.02.006_bib1","article-title":"Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse","author":"Muckle","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.006_bib2","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2105\/AJPH.87.2.221","article-title":"Drug use disorders and treatment contact among homeless adults in Alameda County, California","volume":"87","author":"Robertson","year":"1997","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s004060050063","article-title":"Alcoholism in homeless men in the mid-nineties: results from the Bavarian Public Health Study on homelessness","volume":"249","author":"Fichter","year":"1999","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib4","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1071\/AH09824","article-title":"A\u00a0'snap shot' of the health of homeless people in inner Sydney: St Vincent's Hospital","volume":"35","author":"Chin","year":"2011","journal-title":"Aust Health Rev"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.006_bib5","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1034\/j.1600-0447.2001.00192.x","article-title":"Mortality among homeless people with schizophrenia in Sydney, Australia: a 10-year follow-up","volume":"103","author":"Babidge","year":"2001","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.mcna.2018.02.006_bib6","series-title":"Feasibility of a Managed Alcohol Program (MAP) for Sydney's homeless","author":"Ezard","year":"2015"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib7","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1503\/cmaj.1041350","article-title":"Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol","volume":"174","author":"Podymow","year":"2006","journal-title":"CMAJ"},{"key":"10.1016\/j.mcna.2018.02.006_bib8","series-title":"Evaluation of a managed alcohol program in Vancouver, BC: Early findings and reflections on alcohol harm reduction","author":"Stockwell","year":"2003"},{"key":"10.1016\/j.mcna.2018.02.006_bib9","unstructured":"Managed alcohol: housing, health and hospital diversion. Available at: https:\/\/www.london.ca\/residents\/neighbourhoods\/Documents\/Managed%20Alcohol%20Report.pdf. Accessed March 21, 2018."},{"issue":"7","key":"10.1016\/j.mcna.2018.02.006_bib10","first-page":"888","article-title":"Shelter \"goes wet,\" opens infirmary to cater to Toronto's homeless","volume":"168","author":"Wilton","year":"2003","journal-title":"CMAJ"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib11","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12954-016-0103-4","article-title":"Do managed alcohol programs change patterns of alcohol consumption and reduce related harm? A pilot study","volume":"13","author":"Vallance","year":"2016","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.mcna.2018.02.006_bib12","series-title":"Towards alcohol harm reduction: preliminary results from an evaluation of a Canadian managed alcohol program","author":"Pauly","year":"2013"},{"key":"10.1016\/j.mcna.2018.02.006_bib13","first-page":"ii80","article-title":"Addressing psychiatric disease in homeless individuals with chronic alcoholism","volume":"80","author":"Haney","year":"2003","journal-title":"J\u00a0Urban Health"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib14","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12954-016-0102-5","article-title":"Finding safety: a pilot study of managed alcohol program participants' perceptions of housing and quality of life","volume":"13","author":"Pauly","year":"2016","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.mcna.2018.02.006_bib15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.healthplace.2015.02.011","article-title":"\"This place has given me a reason to care\": understanding 'managed alcohol programs' as enabling places in Canada","volume":"33","author":"Evans","year":"2015","journal-title":"Health Place"},{"key":"10.1016\/j.mcna.2018.02.006_bib16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/1471-2458-12-312","article-title":"Harm reduction services as a point-of-entry to and source of end-of-life care and support for homeless and marginally housed persons who use alcohol and\/or illicit drugs: a qualitative analysis","volume":"12","author":"McNeil","year":"2012","journal-title":"BMC Public Health"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.006_bib17","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/add.12440","article-title":"Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone","volume":"109","author":"Beck","year":"2014","journal-title":"Addiction"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.006_bib18","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/JCP.0000000000000288","article-title":"Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial","volume":"35","author":"Falcato","year":"2015","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"6","key":"10.1016\/j.mcna.2018.02.006_bib19","article-title":"Slow-release oral morphine as maintenance therapy for opioid dependence","author":"Ferri","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.006_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000368572","article-title":"Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study","volume":"21","author":"Verthein","year":"2015","journal-title":"Eur Addict Res"},{"issue":"4","key":"10.1016\/j.mcna.2018.02.006_bib21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jsat.2014.05.012","article-title":"Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence","volume":"47","author":"Hammig","year":"2014","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"11","key":"10.1016\/j.mcna.2018.02.006_bib22","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","article-title":"Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression","volume":"103","author":"Kastelic","year":"2008","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.mcna.2018.02.006_bib23","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/jama.2016.9795","article-title":"Clinical management of opioid use disorder","volume":"316","author":"Dunlap","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.mcna.2018.02.006_bib24","unstructured":"Wood E, AK, Djurfors C, et\u00a0al. A guideline for the clinical management of opioid addiction. 2015. Available at: http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/06\/BC-OUD-Guidelines_June2017.pdf. Accessed July 20, 2017."},{"key":"10.1016\/j.mcna.2018.02.006_bib25","unstructured":"Strang J, Groshkova T, Metrevian N. New heroin-assisted treatment: recent evidence and current practices of supervised injectable heroin treatment in Europe and beyond. Available at: http:\/\/www.emcdda.europa.eu\/system\/files\/publications\/690\/Heroin_Insight_335259.pdf. Accessed March 21, 2018."},{"issue":"4","key":"10.1016\/j.mcna.2018.02.006_bib26","first-page":"552","article-title":"Heroin-assisted Treatment (HAT) a decade later: a brief update on science and politics","volume":"84","author":"Fischer","year":"2007","journal-title":"J\u00a0Urban Health"},{"issue":"8","key":"10.1016\/j.mcna.2018.02.006_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1056\/NEJMoa0810635","article-title":"Diacetylmorphine versus methadone for the treatment of opioid addiction","volume":"361","author":"Oviedo-Joekes","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2018.02.006_bib28","article-title":"Heroin maintenance for chronic heroin-dependent individuals","author":"Ferri","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.mcna.2018.02.006_bib29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1001\/jamapsychiatry.2016.0109","article-title":"Hydromorphone compared with diacetylmorphine for long-term opioid dependence: a randomized clinical trial","volume":"73","author":"Oviedo-Joekes","year":"2016","journal-title":"JAMA Psychiatry"},{"issue":"1","key":"10.1016\/j.mcna.2018.02.006_bib30","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1192\/bjp.bp.114.149195","article-title":"Heroin on trial: systematic review and meta-analysis of randomised trials of diamorphine-prescribing as treatment for refractory heroin addiction","volume":"207","author":"Strang","year":"2015","journal-title":"Br J Psychiatry"},{"issue":"2","key":"10.1016\/j.mcna.2018.02.006_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09595230500537175","article-title":"Patients receiving a prescription for diamorphine (heroin) in the United Kingdom","volume":"25","author":"Metrebian","year":"2006","journal-title":"Drug Alcohol Rev"},{"issue":"9291","key":"10.1016\/j.mcna.2018.02.006_bib32","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(01)06529-1","article-title":"Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study","volume":"358","author":"Rehm","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2018.02.006_bib33","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jsat.2016.06.005","article-title":"Loss of treatment benefit when heroin-assisted treatment is stopped after 12\u00a0months","volume":"69","author":"Demaret","year":"2016","journal-title":"J\u00a0Subst Abuse Treat"},{"issue":"7410","key":"10.1016\/j.mcna.2018.02.006_bib34","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/bmj.327.7410.310","article-title":"Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials","volume":"327","author":"van den Brink","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.mcna.2018.02.006_bib35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.drugalcdep.2017.02.021","article-title":"Safety profile of injectable hydromorphone and diacetylmorphine for long-term severe opioid use disorder","volume":"176","author":"Oviedo-Joekes","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.006_bib36","unstructured":"Injectable opioid agonist treatment for opioid use disorder guidance document. BC Centre on Substance Use. Guidance for injectable opioid agonist treatment for opioid use disorder. Available at: http:\/\/www.bccsu.ca\/wp-content\/uploads\/2017\/10\/BC-iOAT-Guidelines-10.2017.pdf. Accessed March 21, 2018."},{"key":"10.1016\/j.mcna.2018.02.006_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2014.10.012","article-title":"Supervised injection services: what has been demonstrated? A systematic literature review","volume":"145","author":"Potier","year":"2014","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.006_bib38","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(10)62353-7","article-title":"Reduction in overdose mortality after the opening of North America\u2019s first medically supervised safer injecting facility: a retrospective population-based study","volume":"377","author":"Marshall","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2018.02.006_bib39","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S0140-6736(05)66475-6","article-title":"Safer injection facility use and syringe sharing in injection drug users","volume":"366","author":"Kerr","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.mcna.2018.02.006_bib40","first-page":"35","article-title":"Changes in injecting practices associated with the use of a medically supervised safer injection facility","volume":"29","author":"Stoltz","year":"2007","journal-title":"J\u00a0Public Health (Oxf)"},{"key":"10.1016\/j.mcna.2018.02.006_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1477-7517-5-32","article-title":"The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility","volume":"5","author":"Fast","year":"2008","journal-title":"Harm Reduct J"},{"key":"10.1016\/j.mcna.2018.02.006_bib42","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.drugpo.2008.01.003","article-title":"Nurse delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver\u2019s supervised injection facility","volume":"19","author":"Wood","year":"2008","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.mcna.2018.02.006_bib43","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1056\/NEJMc052939","article-title":"Attendance at supervised injecting facilities and use of detoxification services","volume":"354","author":"Wood","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mcna.2018.02.006_bib44","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2010.07.023","article-title":"Injection drug use cessation and use of North America\u2019s first medically supervised safer injecting facility","volume":"113","author":"DeBeck","year":"2011","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.mcna.2018.02.006_bib45","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1503\/cmaj.1040774","article-title":"Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users","volume":"171","author":"Wood","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.mcna.2018.02.006_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1747-597X-1-13","article-title":"Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime","volume":"1","author":"Wood","year":"2006","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"10.1016\/j.mcna.2018.02.006_bib47","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.drugpo.2009.03.004","article-title":"A\u00a0cost-benefit and cost-effectiveness analysis of Vancouver\u2019s supervised injection facility","volume":"21","author":"Andresen","year":"2010","journal-title":"Int J Drug Policy"},{"key":"10.1016\/j.mcna.2018.02.006_bib48","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1503\/cmaj.080808","article-title":"The cost-effectiveness of Vancouver\u2019s supervised injection facility","volume":"179","author":"Bayoumi","year":"2008","journal-title":"CMAJ"},{"key":"10.1016\/j.mcna.2018.02.006_bib49","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1360-0443.2010.02977.x","article-title":"Is Vancouver Canada\u2019s supervised injection facility cost-saving?","volume":"105","author":"Pinkerton","year":"2010","journal-title":"Addiction"},{"key":"10.1016\/j.mcna.2018.02.006_bib50","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.drugpo.2011.03.003","article-title":"How many HIV infections are prevented by Vancouver Canada\u2019s supervised injection facility?","volume":"22","author":"Pinkerton","year":"2011","journal-title":"Int J Drug Policy"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300105?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712518300105?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,13]],"date-time":"2018-08-13T23:05:24Z","timestamp":1534201524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712518300105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,7]]}},"alternative-id":["S0025712518300105"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.006","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nontraditional Alcohol and Opioid Agonist Treatment Interventions","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2018.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}